China has sharply restricted investigator-initiated biotech clinical trials after patient deaths, slowing what had been a surge of controversial studies. The change leaves rare disease families with fewer trial options and creates uncertainty for US investors exposed to China’s biotech sector. It matters because tighter oversight may improve safety but could also delay access and complicate cross-border investment.
Clinical TrialsEthics & SafetyCell Therapy Industry
Two industry experts, Sun Chau Siu and Kaisong Zhou, offer a point of view on what biotech licensing actually delivers, focusing on the often-overlooked difficulties of transferring intellectual property between organizations. Their commentary draws attention to execution challenges that sit beyond the deal terms themselves. For professionals working in licensing or technology transfer, the piece serves as a reminder that securing rights is only part of the task.
India has proposed rules that would require regulators to immediately suspend manufacturing licenses when government testing shows a drug fails quality standards. For industry professionals, the move signals tighter enforcement and higher compliance risk for manufacturers, with potential implications for supply continuity and quality assurance.
Clinical TrialsEthics & SafetyCell Therapy IndustryRead more →
A sickle cell gene-editing therapy that had been in development for a decade was abruptly halted three years ago after the first treated patient experienced a serious adverse event. The program now appears to have a chance at revival. For professionals in gene therapy and hematology, the development is notable because it could reopen a once-abandoned editing approach for a disease with limited curative options.
Novartis has confirmed nine cases of tumors in children treated with its gene therapy Zolgensma. In two of those cases, the company said testing showed evidence that the viral vector had integrated into patients' DNA; both children received treatment and continue to be monitored. The disclosure matters because vector integration and possible insertional oncogenesis are key long-term safety concerns for gene therapies, and the cases are likely to draw closer regulatory and clinical scrutiny.
Revolution Medicines’ pancreatic cancer drug Rasonque has gotten off to an exceptionally strong commercial start, with its debut described as one of the best oncology launches in history. The early uptake matters because it signals rapid adoption in a difficult-to-treat cancer and could meaningfully shape expectations for the company’s commercial prospects.
Senator Bernie Sanders, a longtime critic of the pharmaceutical industry, is positioned to play a significant role in shaping the legislation that funds the FDA. The report says he could use that influence during drafting to press for reforms. Because FDA funding measures often carry substantive policy changes, his involvement matters for drugmakers, regulators, and others tracking the agency's direction.
Regulation & ApprovalCell Therapy IndustryRead more →
New tumor cases have been reported in patients treated with AAV-based gene therapies such as Zolgensma, indicating that the widely used delivery tool may carry an oncogenic risk. The findings raise concerns for SMA patients and for gene therapy researchers assessing long-term safety. Because AAV vectors underpin many gene therapy programs, the reports could affect risk-benefit evaluations and safety monitoring across the field.
Medicare has delayed until 2029 a controversial remote patient monitoring policy that would stop providers such as hospitals from using third parties to deliver those services, despite broad opposition. The decision matters because it postpones a major change for hospitals and RPM vendors while signaling that Medicare still intends to restrict third-party arrangements.
A webinar will feature two experts explaining how ultra-sensitive, multiplexed proteomics can measure the pace of biological aging and assess interventions designed to change it. The discussion matters because reliable proteomic measures could help track aging trajectories and evaluate whether candidate treatments are having an effect.
Rose BioSolutions CEO David Enloe argues that developers of advanced therapies should rethink how they work with contract development and manufacturing organizations, moving beyond a transactional outsourcing model. He contends that complex biologics and cell and gene therapies require earlier joint problem-solving, deeper scientific collaboration, and shared accountability between sponsors and manufacturers. The commentary matters for biotech leaders choosing manufacturing partners, since misaligned incentives and late-stage handoffs can translate into costly delays and quality risk.
Regulation & ApprovalCell Therapy IndustryRead more →
An oral therapy for obstructive sleep apnea that targets multiple pathways is positioned to add to existing treatment choices. It is expected to improve patient compliance and may lead to better outcomes, though the excerpt does not specify trial results or regulatory status.
Advocates for a single-payer health system received a notable political opening this election, with Sen. Bernie Sanders likely to lead the Senate health committee next year. That role could give him a platform to fundamentally reshape how the FDA interacts with the companies it regulates. For professional readers, the shift signals a potentially more confrontational federal health oversight agenda and new pressure on industry relationships.
